On January 17, 2023 Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, reported that new data from its portfolio of blood tests will be presented at the ASCO (Free ASCO Whitepaper) 2023 Gastrointestinal Cancers Symposium, January 19-21 in San Francisco (Press release, Guardant Health, JAN 17, 2023, View Source [SID1234626295]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The 10 poster presentations highlight the use of the Guardant360 and Guardant RevealTM blood tests and the GuardantINFORMTM real-world evidence dataset to identify critical biomarkers and acquired co-mutations, track associated treatment patterns and clinical outcomes, and predict disease recurrence from minimal residual disease (MRD) detection.
"We look forward to sharing new data at the ASCO (Free ASCO Whitepaper) GI Symposium demonstrating the utility of our blood tests and real-world data to increase the understanding of potential biomarker targets for therapy, as well as predictive markers for treatment resistance and disease recurrence in patients with gastrointestinal cancers," said Helmy Eltoukhy, Guardant Health co-CEO. "The presentations will show how data from circulating tumor DNA tests provide critical insights that can contribute to the development of more effective therapies and better-informed patient care."
Full List of Guardant Health Presentations
Guardant360
ctDNA-based fusion detection for advanced colorectal cancer with a partner-agnostic assay (abstract 186)
FGFR2-amplified gastroesophageal adenocarcinoma is a distinct genomic class: Lessons learned from a liquid biopsy platform (abstract 429)
A plasma-based analysis and genomic landscape of patients with high tumor mutational burden (TMB-H), microsatellite stable (MSS) colorectal cancer (CRC) (abstract 249)
Frequency and outcomes of BRAF alterations identified by liquid biopsy in metastatic non-colorectal gastrointestinal cancers (abstract 808)
The identification of reversion mutations in patients with advanced pancreatic cancer and germline or somatic BRCA or PALB2 variants who were treated with maintenance rucaparib (abstract 734)
Circulating tumor DNA-based genomic landscape of KRAS wild-type pancreatic adenocarcinoma (abstract 747)
Effect of EGFR and ERBB2 amplifications and activating alterations on efficacy of lenvatinib in hepatocellular carcinoma (abstract 600)
GuardantINFORM
Use of circulating tumor DNA (ctDNA) for early assessment of treatment response in patients with advanced colorectal cancer (aCRC): A real-world (RW) analysis (abstract 246)
Guardant Reveal
Optimising longitudinal plasma-only circulating tumour DNA (ctDNA) for minimal residual disease (MRD) detection with combined genomic/methylation signals to predict recurrence in patients (pts) with resected stage I-III colorectal cancer (CRC) in the UK multicentre prospective study TRACC (abstract 169) (Merit Award recipient)
Plasma-only multiomic minimal residual disease (MRD) testing in 2,000 consecutive patients with colorectal cancer (CRC) (abstract 28)
The full abstracts are available on the officialASCO 2023 GI Cancers Symposiumwebsite.